Kallisio’s Stentra Receives CE Mark for Precision Oral Immobilization System in Head & Neck Radiation Therapy

Why It Matters

The approval enables rapid clinical adoption in the EU, potentially raising the standard of care for head‑and‑neck cancer radiotherapy and creating a new revenue stream for Kallisio.

Key Takeaways

• CE mark granted under EU MDR 2017/745
• Stentra offers millimeter‑accurate oral immobilization
• No changes needed to treatment planning systems
• Pilot sites launch in Germany this year
• Enhances patient comfort and organ‑at‑risk protection

Pulse Analysis

The CE marking of Kallisio’s Stentra system marks a pivotal regulatory milestone in Europe’s radiation oncology landscape. Under the stringent EU MDR 2017/745, the certification validates the device’s safety and performance, positioning Kallisio to tap into a market that values precision and compliance. As European cancer centers increasingly adopt advanced immobilization technologies, Stentra’s approval could accelerate broader acceptance of patient‑specific solutions across the continent.

Stentra leverages design automation and rapid 3‑D manufacturing to create a custom intraoral device for each patient. By integrating directly into existing workflows—without requiring modifications to treatment planning software, IT systems, or data pipelines—the solution minimizes implementation friction. The millimeter‑accurate stabilization reduces organ‑at‑risk movement, enabling higher radiation doses to tumors while preserving surrounding tissue. Moreover, the ergonomic design improves patient comfort, potentially decreasing treatment interruptions and enhancing overall compliance.

Clinically, the German pilot sites will provide early performance data that could inform reimbursement strategies and guide expansion into other EU markets. Success may also prompt Kallisio to pursue U.S. FDA clearance, opening a sizable North American market where precision radiotherapy is a growth priority. Competitors offering generic immobilization aids will face pressure to adopt similar customization capabilities, driving innovation across the sector. Ultimately, Stentra’s entry could raise the bar for head‑and‑neck cancer treatment, delivering better outcomes and reinforcing Europe’s reputation for medical‑device excellence.